Key Takeaways
- • Vie Ventures, a new Boston-based life sciences investment firm, officially launched to invest in private biotech companies developing novel therapeutics for autoimmune and immune system disorders.
- • The firm will focus primarily on Series B and C-stage private biotech companies, according to the company's Business Wire announcement.
- • Co-founded by Steven St. Peter, M.D., former Managing Director of The T1D Fund, and Luke Evnin, Ph.D., co-founder of MPM Capital, where the pair worked together for a decade across three venture funds.
- • The firm's initial strategic collaborators include the Crohn's and Colitis Foundation, Lupus Research Alliance, National Multiple Sclerosis Society, Scleroderma Research Foundation, and Sjögren's Foundation.
Summary
Vie Ventures, a life sciences investment firm headquartered in Boston, announced its official launch on July 9, 2025, positioning itself at the intersection of venture capital and disease philanthropy. According to the company's Business Wire release, the firm will invest alongside other leading venture capital investors and strategic partners, primarily in Series B and C-stage private biotechnology companies developing novel therapeutics for autoimmune disease and other disorders of the immune system.
The firm is co-founded by Steven St. Peter, M.D., and Luke Evnin, Ph.D., who previously worked together for a decade at MPM Capital, where they invested three successive venture capital funds. St. Peter most recently served as Managing Director of The T1D Fund, the venture philanthropy arm of Breakthrough T1D (formerly JDRF), which he helped grow into one of the largest disease-focused venture philanthropy funds globally, with more than $200 million in assets. Evnin co-founded MPM Capital and chairs the Scleroderma Research Foundation, where he has served on the board for over 25 years.
Vie Ventures has launched with initial strategic collaborators including the Crohn's and Colitis Foundation, Lupus Research Alliance, National Multiple Sclerosis Society, Scleroderma Research Foundation, and Sjögren's Foundation. Lou DeGennaro, Ph.D., former CEO of the Leukemia & Lymphoma Society, serves as Senior Advisor and leads collaborator engagement. The co-founders have also pledged a share of their proceeds and time to philanthropy, including the formation of the Vie Ventures Foundation, a public charity focused on the prevention, diagnosis, and treatment of autoimmune and inflammatory diseases.
In describing the firm's rationale, St. Peter said the team aims to serve as a bridge between disease-focused philanthropies and for-profit therapeutics developers, a model he argued would support more informed investment decisions and value-added partnership with portfolio companies. The release does not disclose fund size, committed capital, or specific portfolio investments.
The firm is co-founded by Steven St. Peter, M.D., and Luke Evnin, Ph.D., who previously worked together for a decade at MPM Capital, where they invested three successive venture capital funds. St. Peter most recently served as Managing Director of The T1D Fund, the venture philanthropy arm of Breakthrough T1D (formerly JDRF), which he helped grow into one of the largest disease-focused venture philanthropy funds globally, with more than $200 million in assets. Evnin co-founded MPM Capital and chairs the Scleroderma Research Foundation, where he has served on the board for over 25 years.
Vie Ventures has launched with initial strategic collaborators including the Crohn's and Colitis Foundation, Lupus Research Alliance, National Multiple Sclerosis Society, Scleroderma Research Foundation, and Sjögren's Foundation. Lou DeGennaro, Ph.D., former CEO of the Leukemia & Lymphoma Society, serves as Senior Advisor and leads collaborator engagement. The co-founders have also pledged a share of their proceeds and time to philanthropy, including the formation of the Vie Ventures Foundation, a public charity focused on the prevention, diagnosis, and treatment of autoimmune and inflammatory diseases.
In describing the firm's rationale, St. Peter said the team aims to serve as a bridge between disease-focused philanthropies and for-profit therapeutics developers, a model he argued would support more informed investment decisions and value-added partnership with portfolio companies. The release does not disclose fund size, committed capital, or specific portfolio investments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.